Please login to the form below

Not currently logged in
Email:
Password:

Mochida and Wyeth in novel vanilloid pain tie-up

Mochida licenses a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals

Mochida Pharmaceutical has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals.

Per the Agreement, Wyeth wins an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists. Mochida will receive an upfront payment and potential development milestone payments, as well as royalties on sales by Wyeth.

Mochida retains an option to co-develop and co-market in Japan with Wyeth.

TRPV1 is a receptor and ion channel, which is stimulated by various stimuli including capsaicin, an ingredient derived from chilli peppers.

A number of other large pharmaceutical companies are also researching TRPV1 receptors for use in reducing nociception from inflammatory and neuropathic pain models in rats. In humans, drugs acting at TRPV1 receptors could potentially be used to treat neuropathic pain associated with multiple sclerosis, chemotherapy, or amputation, as well as pain associated with the inflammatory response of damaged tissue, such as in osteoarthritis. Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

14th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...

Infographics